Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 45

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 45
---
’ Equity

    Current liabilities:

    Accounts payable
     
    $
    214,442

    $
    164,918

    Accrued expenses

    373,513

    314,997

    Deferred revenue, current portion

    130,256

    50,416

    Current portion of long-term debt

    —

    105,483

    Other current liabilities

    13,473

    17,845

    Total current liabilities

    731,684

    653,659

    Long-term debt

    1,137,124

    1,132,515

    Lease liabilities, net of current portion

    192,473

    140,965

    Deferred revenue, net of current portion

    325,000

    437,000

    Contingent consideration

    47,400

    38,100

    Other non-current liabilities

    1,750

    3,000

    Total liabilities

    2,435,431

    2,405,239

    Commitments and contingencies (Note 22)

    Stockholders’ equity:

    Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and   outstanding

    —

    —

    Common stock, $0.0001 par value, 198,000,000 shares authorized; 96,900,496   and 93,731,831 issued and outstanding at December 31, 2024 and 2023,    respectively

    10

    9

    Additional paid-in capital

    5,738,924

    5,304,623

    Accumulated other comprehensive (loss) income, net of tax

    (218
    )

    918

    Accumulated deficit

    (4,210,974
    )

    (4,446,213
    )

    Total stockholders’ equity

    1,527,742

    859,337

    Total liabilities and stockholders’ equity
     
    $
    3,963,173

    $
    3,264,576

See accompanying notes to consolidated financial statements.

F-4

Sarepta Therapeutics, Inc.

Consolidated Statements of Comprehensive Income (Loss)

(in thousands